Recro Pharma, Inc. (REPH) Social Stream
Recro Pharma Inc (REPH) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering REPH.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-12-01 | 2 | $5 | $5 | $5 | $2.1 | 138.1% |
The Trend in the Analyst Price Target
Over the past 29 weeks, REPH's average price target has gone down $0.5.
Over the past 34 weeks, REPH's average upside potential has been 118.94%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-04-09 | 1 | 6 | 5 | 5.5 | 3.26 | 68.71% |
| 2021-07-01 | 1 | 6 | 5 | 5.5 | 2.20 | 150% |
| 2021-08-19 | 1 | 6 | 5 | 5.5 | 2.50 | 120% |
| 2021-09-02 | 2 | 5 | 5 | 5.0 | 2.45 | 104.08% |
| 2021-12-01 | 2 | 5 | 5 | 5.0 | 1.48 | 237.84% |
REPH Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 2 | 0 | 0 | 0 | 0 | 2 |
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- Recro Pharma Inc's variance in analysts' estimates is lower than just about 100% of all US stocks.
- In the context of Healthcare stocks, Recro Pharma Inc's number of analysts covering the stock is greater than 4.65% of them.
- In the context of Healthcare stocks, Recro Pharma Inc's average analyst price target is greater than 5.18% of them.
- Recro Pharma Inc's upside potential (average analyst target price relative to current price) is higher than 62.5% of stocks in the small market cap category.
In the Pharmaceutical Products industry, RDHL, RAPT, and RANI are the three stocks most similar to Recro Pharma Inc regarding the price target and analyst recommendation information presented here.
Is REPH a Buy, Hold or Sell? See the POWR Ratings now!